StockCIK 1668243
UroGen Pharma Ltd. (URGN): Insider Trades and Fund Holdings
In the past 12 months, UroGen Pharma Ltd. insiders reported 0 open-market purchases worth $0 and 4 sales worth $3.04M; 0 of the sales were reported as made under a 10b5-1 trading plan.
0Insider buys, 12 months
$0Bought by insiders, 12 months
$3.04MSold by insiders, 12 months
1Tracked funds holding
Recent insider trades
Open-market purchases (code P) and sales (code S) from Form 4. Grants, option exercises and gifts are not shown. Latest filing: Oct 9, 2026.
| Filed | Insider | Type | Value |
|---|---|---|---|
| Oct 9 | Chris DegnanCFO | ▼ SELL | $81K |
| Sep 9 | Jason Drew SmithGeneral Counsel | ▼ SELL | $65K |
| Sep 9 | Mark SchoenbergChief Medical Officer | ▼ SELL | $37K |
| Aug 24 | Mark SchoenbergChief Medical Officer | ▼ SELL | $2.85M |
Source: SEC Form 4 filings, retrieved Oct 28, 2026. How we read filings
Insiders who traded in the past year
| Insider | Role | Buys | Bought | Sells | Sold |
|---|---|---|---|---|---|
| Chris Degnan | CFO | 0 | $0 | 1 | $81K |
| Jason Drew Smith | General Counsel | 0 | $0 | 1 | $65K |
| Mark Schoenberg | Chief Medical Officer | 0 | $0 | 2 | $2.89M |
Tracked funds that report URGN
From each fund's latest 13F. Holdings are as of quarter end and are filed up to 45 days later.
| Fund | Shares | Value | Change |
|---|---|---|---|
| Renaissance Technologies | 70,300 | $2.59M | ▲ New |
Source: SEC Form 13F-HR filings, retrieved Oct 28, 2026. How we read filings
Reading these numbers
Insiders sell for many reasons: taxes, diversification, a house. Purchases with their own money are rarer and are usually read as more informative. A Form 4 is due within two business days of the trade. How to read a Form 4 →